US Patent

US11224572 — Stable oral liquid composition of terazosin

Method of Use · Assigned to Novitium Pharma LLC · Expires 2041-02-01 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a stable oral liquid composition of terazosin, useful for treating symptomatic benign prostatic hyperplasia and hypertension.

USPTO Abstract

The present invention relates to novel stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension.

Drugs covered by this patent

terazosin-hydrochloride (TERAZOSIN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3990`	—	terazosin-hydrochloride

Patent Metadata

Patent number: US11224572
Jurisdiction: US
Classification: Method of Use
Expires: 2041-02-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Novitium Pharma LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.